GlassScriptPhysician profile
Trinh Doan
NPI 1518966878
$2,003.80
in general payments reported to CMS, 2019-2025
23 companies · $944 in 2025
The $944 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $152 · 2024: $908 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $302.04 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $276.71 | 2024-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $140.70 | 2023-2025 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $107.71 | 2025 | Zenpep |
| Abbott Laboratories | $94.21 | 2023-2025 | Octrode, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.26 | 2023-2025 | Jardiance, Tradjenta |
| Corcept Therapeutics | $72.72 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $72.28 | 2024-2025 | Inspire |
| Lilly USA, LLC | $71.57 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $64.51 | 2024-2025 | |
| Abbvie INC. | $55.32 | 2023-2024 | Ubrelvy |
| Medtronic, INC. | $45.24 | 2024 | Interstim, Intellis Adaptivestim |
| Mallinckrodt Hospital Products INC. | $31.97 | 2024 | Terlivaz |
| Sanofi-Aventis U.S. LLC | $25.54 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.61 | 2025 | Rexulti |
| Cequr Corporation | $23.10 | 2025 | Cequr Simplicity |
| Biotronik Nro, INC. | $18.02 | 2024 | Prospera |
| Tolmar, INC. | $17.30 | 2025 | Jatenzo |
| Dexcom, INC. | $15.82 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.27 | 2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $15.27 | 2025 | Unithroid |
| Pfizer INC. | $13.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinh Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.